Secretory phospholipase A2 (sPLA2) (Type V) is a calcium-dependent phospholipase A2 superfamily member that is encoded by PLA2G5 in humans.1 It is composed of a highly conserved calcium-binding loop, a heparin-binding domain, and a C-terminal domain that contains a catalytic histidine-aspartic acid dyad and cationic residues that are essential for cell membrane association. Pla2g5 is constitutively expressed in the heart, lung, and spleen and is induced by proinflammatory stimuli in a variety of immune cells and tissues.2 Upon activation, sPLA2 (Type V) is released into the extracellular space where it acts in a paracrine or autocrine manner to catalyze the hydrolysis of fatty acids at the sn-2 position of glycerophospholipids, liberating the free fatty acid and lysophospholipid, which serve as substrates for the synthesis of bioactive lipid metabolites.1 Pla2g5-/- mice have decreased airway and bronchoalveolar lavage fluid (BALF) neutrophil infiltration in a model of acute lung injury induced by LPS.3 Neonatal mice overexpressing Pla2g5 have increased BALF prostaglandin E2 (PGE2; Item No. 14010) levels, as well as reduced lung surfactant levels, leading to respiratory failure and death by postnatal day one.4 SNPs in PLA2G5 are associated with increased plasma LDL and total cholesterol levels in individuals with type 2 diabetes.5 Cayman's sPLA2 (mouse Type V) Polyclonal Antibody can be used for Western blot applications. The antibody recognizes sPLA2 (Type V) at 16 kDa from human, mouse, and rat samples.WARNING This product is not for human or veterinary use.
